Orchid Orthopedic Solutions is proud to announce the promotions of two key individuals. First, Joe Zuzula has been named Vice President of Sales and Marketing. Zuzula has spent 19 years at Orchid, and has demonstrated “an uncanny ability to manage a sales and marketing staff and to drive the sales throughout Orchid.” Zuzula is known for keeping the sales staff both motivated and accountable while cultivating strong relationships with customers and media partners. He is a graduate of Michigan State University with a B.S. in Physical Science Secondary Education with a minor in Mathematics.
Joe Zuzula, Bill Ditty Promoted at Orchid Orthopedic Solutions

Second, Bill Ditty is being elevated to the position of Vice President of Quality and Regulatory Compliance for Orchid. Ditty has been serving as Director of Quality and has done “an outstanding job of advancing Orchid’s quality team.” He has successfully led the company through the new FDA registration requirements. Ditty possesses a broad base of experience at companies such as Monteris Medical and Stryker Instruments. He spent eight years as an officer in the Coast Guard, has an M.B.A. in Finance and a B.S. in Naval Architecture and Marine Engineering from the United States Coast Guard Academy.
Asked about his new role Bill Ditty commented to OTW, “In alignment with our mission ‘To provide an Opportunity for People to Live a Better Life’ I will continue to raise global product quality levels by leveraging industry best practices. Also, I will seek to bring value to our customers by identifying changes and opportunities for improvement in the ever changing medical device regulatory climate and ensuring we have the correct resources in place to proactively manage them.”
Joe Zuzula noted, “I will begin by participating in the regular executive team meetings with the CEO, CFO, CAO and EVPs. I will provide input into our long term strategy for growth and will support board of director initiatives such as our three year management plan. My continued focus will be on expanding in new geographic markets such as Europe, South America and Asia and aligning our global sales organization with our strategic goals for process and growth. I will also reach to expand our acumen in intelligence about our markets.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.